Fasting adiponectin is inversely correlated with metabolic syndrome in patients with coronary artery disease

Internal Medicine

Volumn 49, Issue 8, 2010, Pages 739-747

  Wang, Ji Hung ^a   Lee, Chung Jen ^b   Lee, Chia Chi ^b   Chen, Yu Chih ^a   Lee, Ru Ping ^c   Hsu, Bang Gee ^a,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Adiponectin; Coronary artery disease; Metabolic syndrome

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; PREVALENCE; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FASTING; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 77951223621     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3093     Document Type: Article

References (43)

1. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23: 469-480, 2006.
2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
3. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement Circulation 112: 2735-2752, 2005.
4. Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L. Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol 103: 523-527, 2009.
5. Solymoss BC, Bourassa MG, Marcil M, Levesque S, Varga S, Campeau L. Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronaryangiographic alterations. Coron Artery Dis 20: 1-8, 2009.
6. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8: 264-280, 2006.
7. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27: 762-778, 2006.
8. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18: 263-270, 2007.
9. Tajtákova M, Petrásova D, Petrovicová J, Pytliak M, Semanová Z. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocr Regul 40: 15-19, 2006.
10. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes 32: 772-779, 2008.
11. Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: 85-89, 2003.
12. Otsuka F, Sugiyama S, Kojima S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 48: 1155-1162, 2006.
13. Hashimoto N, Kanda J, Nakamura T, et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 55: 1653-1657, 2006.
14. Frystyk J, Berne C, Berglund L, et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92: 571-576, 2007.
15. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363: 157-163, 2004.
16. Lee CC, Lee RP, Subeq YM, Wang CH, Fang TC, Hsu BG. Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 39: 785-790, 2008.
17. Wang JH, Subeq YM, Tsai WC, Lee RP, Hsu BG. Intravenous Nacetylcysteine with saline hydration improves renal function and ameliorates plasma total homocysteine in patients undergoing cardiac angiography. Ren Fail 30: 527-533, 2008.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
19. Anuurad E, Chiem A, Pearson TA, Berglund L. Metabolic syndrome components in african-americans and European-american patients and its relation to coronary artery disease. Am J Cardiol 100: 830-834, 2007.
20. Rhee EJ, Lee WY, Park CY, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 160: 165-172, 2009.
21. Saely CH, Risch L, Hoefle G, et al. Low serum adiponectin is independently associated with both the metabolic syndrome and angiographically determined coronary atherosclerosis. Clin Chim Acta 383: 97-102, 2007.
22. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866, 2002.
23. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106: 2767-2770, 2002.
24. Otsuka F, Sugiyama S, Kojima S, et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 71: 1703-1709, 2007.
25. Tretjakovs P, Jurka A, Bormane I, et al. Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. Eur J Intern Med 20: 712-717, 2009.
26. Selcuk MT, Selcuk H, Temizhan A, et al. Impact of plasma adiponectin levels to the presence and severity of coronary artery disease in patients with metabolic syndrome. Coron Artery Dis 19: 79-84, 2008.
27. Hitsumoto T, Takahashi M, Iizuka T, Shirai K. Relationship between metabolic syndrome and early stage coronary atherosclerosis. J Atheroscler Thromb 14: 294-302, 2007.
28. Hwang JJ, Yang WS, Chiang FT, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 204: 293-297, 2009.
29. Rizza S, Clementi F, Porzio O, et al. Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. Nutr Metab Cardiovasc Dis 19: 54-60, 2009.
30. Kojima S, Funahashi T, Maruyoshi H, et al. Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res 115: 483-490, 2005.
31. Liang KW, Sheu WH, Lee WL, et al. Decreased circulating protective adiponectin level is associated with angiographic coronary disease progression in patients with angina pectoris. Int J Cardiol 129: 76-80, 2008.
32. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114: 623-629, 2006.
33. Yilmaz MI, Sonmez A, Caglar K, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 12: 147-153, 2007.
34. Zyriax BC, Algenstaedt P, Hess UF, et al. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study. Atherosclerosis 200: 403-409, 2008.
35. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792, 2006.
36. Kim OY, Koh SJ, Jang Y, et al. Plasma adiponectin is related to other cardiovascular risk factors in nondiabetic Korean men with CAD, independent of adiposity and cigarette smoking: crosssectional analysis. Clin Chim Acta 370: 63-71, 2006.
37. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
38. Nakamura T, Kodama Y, Takano H, et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 193: 449-451, 2007.
39. Gannagé-Yared MH, Azar RR, Amm-Azar M, et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54: 947-951, 2005.
40. Sonmez A, Dogru T, Tasci I, et al. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clin Endocrinol 64: 567-572, 2006.
41. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55: 249-259, 2006.
42. Seino Y, Hirose H, Saito I, Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 56: 1493-1499, 2007.
43. Seino Y, Hirose H, Saito I, Itoh H. High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism 58: 355-360, 2009.